

**RECEIVED  
CENTRAL FAX CENTER**

APR 26 2005

**FAX TRANSMISSION****DATE:** April 26, 2005**PTO IDENTIFIER:** Application Number 10/627,586**Inventor:** Khalid Mekouar et al.**MESSAGE TO:** US Patent and Trademark Office**FAX NUMBER:** (703) 872-9306**FROM:** DARBY & DARBY P.C.

Jeffrey C. Pepe

**PHONE:** (206) 262-8900**Attorney Dkt. #:** 20343/1202385-US1**PAGES (Including Cover Sheet):** 7**CONTENTS:**

Certificate of Transmission (1 page)  
Revocation of Power of Attorney or Authorization of Agent (1 page)  
Statement under 37 CFR 3.73(b) (1 page)  
Copy of Assignment (3 pages)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (206) 262-8900 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

**DARBY & DARBY P.C.**

P.O. Box 5257, New York, New York 10150-5257

Telephone: (212) 527-7700 Facsimile: (212) 527-7701

{S:\20343\9420343-000\80027295.DOC [XXXXXXXXXXXXXXXXXXXX]} 1

PTO/SB/97 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/627,586

Attorney Docket No.: 20343/1202385-US1

## Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office.

on April 26, 2005  
Date



Signature

Linda Povinelli

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Revocation of Power of Attorney or Authorization of Agent (1 page)  
Statement under 37 CFR 3.73(b) (1 page)  
Copy of Assignment (3 pages)

PTO/SB/82 (09-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

|  |                        |                         |
|--|------------------------|-------------------------|
| <b>REVOCATION OF POWER OF ATTORNEY WITH<br/>NEW POWER OF ATTORNEY<br/>AND<br/>CHANGE OF CORRESPONDENCE ADDRESS</b> | Application Number     | 10/627,586-Conf. #2991  |
|  | Filing Date            | July 25, 2003           |
|  | First Named Inventor   | Khalid Mekouar          |
|  | Art Unit               | 1614                    |
|  | Examiner Name          |                         |
|  | Attorney Docket Number | 20343/1202385-US1 (442) |

I hereby revoke all previous powers of attorney given in the above-identified application.

☐ A Power of Attorney is submitted herewith.

OR

☒ I hereby appoint the practitioners associated with the Customer Number: 
☒ Please change the correspondence address for the above-identified application to:

☒ The address associated with  
Customer Number:

OR

☐ Firm or  
Individual Name 

Address

City

Country

State

Zip

Telephone

Fax


I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature



Name

Richard Coulson, VP, Micrologix Biotech Inc.

Date

Telephone

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ \*Total of  forms are submitted.

{W:\MGI\forma\00378680.DOC \*MGI\FORMAL\* } 1

PTO/SB/96 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Khalid Mekouar and Robert DézielApplication No./Patent No.: 10/627,586 Filed/Issue Date: July 25, 2003Entitled: ANTI-VIRAL 7-DEAZA D-NUCLEOSIDES AND USES THEREOFMicrologix Biotech Inc.

(Name of Assignee)

a

corporation(Type of Assignee, e.g., corporation, partnership,  
university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.  
The extent (by percentage) of its ownership interest is \_\_\_\_\_ %

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above.  
The assignment was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the  
current assignee as shown below:

1. From: \_\_\_\_\_ To: \_\_\_\_\_

The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

2. From: \_\_\_\_\_ To: \_\_\_\_\_

The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

3. From: \_\_\_\_\_ To: \_\_\_\_\_

The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title noted in B above are  
attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be  
submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records  
of the USPTO. See MPEP 302.8]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

October 10, 2003

Date

Robert Cory, Ph.D., MBA

Typed or printed name

(604) 221-9666 x 234

Telephone Number



Signature

Vice President of Business Development

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Docket No. 660081.442

418207

**COPY**

## ASSIGNMENT


WHEREAS, we, **Khalid Mekouar**, having the mailing address of 257 Rue Boudrias, Laval, Quebec, Canada H7X4B6 and **Robert Déziel** having the mailing address of 546 Chester Street, Montreal, Quebec, Canada H3R 1W9 (hereinafter referred to as ASSIGNORS), are the joint inventors of an invention entitled "ANTI-VIRAL 7-DEAZA D-NUCLEOSIDES AND USES THEREOF," as described and claimed in the specification for which an application for United States letters patent was filed on July 25, 2003 and assigned Application No. 10/627,586; which application claims the benefit of U.S. Provisional Application No. 60/398,424, filed July 25, 2002;

WHEREAS, **Micrologix Biotech Inc.** (hereinafter referred to as ASSIGNEE), a corporation of the Province of British Columbia, in the country of Canada, having a place of business at 3650 Wesbrook Mall, Vancouver, British Columbia, V6S 2L2, Canada, is desirous of acquiring the entire right, title and interest in and to the invention and in and to any letters patent that may be granted therefor in the United States and in any and all foreign countries;

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNORS hereby sell, assign and transfer unto said ASSIGNEE the entire right, title and interest in and to said invention, said application and any and all letters patent which may be granted for said invention in the United States of America and its territorial possessions and in any and all foreign countries, and in any and all divisions, reissues and continuations thereof, including the right to file foreign applications directly in the name of ASSIGNEE and to claim priority rights deriving from said United States application to which said foreign applications are entitled by virtue of international convention, treaty or otherwise, said invention, application and all letters patent on said invention to be held and enjoyed by ASSIGNEE and its successors and assigns as fully and entirely as the same would have been held and enjoyed by ASSIGNORS had this assignment, transfer and sale not been made. ASSIGNORS hereby authorize and request the Commissioner of Patents and Trademarks to issue all letters patent on said invention to ASSIGNEE. ASSIGNORS agree to execute all instruments and documents required for the making and prosecution of applications for United

Application No. 10/67,586

States and foreign letters patent on said invention, for litigation regarding letters patent, or for the purpose of protecting title to said invention or letters patent therefor.

Date 1 October 2002        
Khalid Mekouar  
City of Laval )  
Province of Quebec ) ss.

I certify that I know or have satisfactory evidence that Khalid Mekouar is the person who appeared before me, and said person acknowledged that he signed this instrument and acknowledged it to be his free and voluntary act for the uses and purposes mentioned in the instrument.

Dated \_\_\_\_\_  
Signature of \_\_\_\_\_  
Notary Public \_\_\_\_\_  
Printed Name \_\_\_\_\_

Application No. 10/67,586

Date October 6, 2003      Robert Déziel  
 City of Montreal      Robert Déziel  
 Province of Quebec      ) ss.

I certify that I know or have satisfactory evidence that Robert Déziel is the person who appeared before me, and said person acknowledged that he signed this instrument and acknowledged it to be his free and voluntary act for the uses and purposes mentioned in the instrument.

Dated \_\_\_\_\_  
 Signature of \_\_\_\_\_  
 Notary Public \_\_\_\_\_  
 Printed Name \_\_\_\_\_

660081.442 / 418209